Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIAT
Ratios

Alx Oncology Holdings (ALXO) EBIAT (2019 - 2023)

Alx Oncology Holdings' EBIAT history spans 5 years, with the latest figure at -$45.5 million for Q4 2023.

  • For Q4 2023, EBIAT fell 48.07% year-over-year to -$45.5 million; the TTM value through Dec 2023 reached -$160.8 million, down 30.23%, while the annual FY2025 figure was -$101.7 million, 24.59% up from the prior year.
  • EBIAT for Q4 2023 was -$45.5 million at Alx Oncology Holdings, up from -$51.0 million in the prior quarter.
  • Across five years, EBIAT topped out at -$3.0 million in Q3 2019 and bottomed at -$51.0 million in Q3 2023.
  • The 5-year median for EBIAT is -$24.5 million (2022), against an average of -$22.6 million.
  • The largest annual shift saw EBIAT plummeted 234.46% in 2020 before it decreased 3.76% in 2023.
  • A 5-year view of EBIAT shows it stood at -$7.8 million in 2019, then plummeted by 141.81% to -$18.8 million in 2020, then tumbled by 51.48% to -$28.4 million in 2021, then fell by 7.99% to -$30.7 million in 2022, then tumbled by 48.07% to -$45.5 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's EBIAT are -$45.5 million (Q4 2023), -$51.0 million (Q3 2023), and -$34.2 million (Q2 2023).